Evolus Stock Earnings Reports

Evolus reported Q1 2026 results showing continued momentum and operational improvements: global net revenue of $73.1M (up 7% YoY) with Jeuveau at $66.4M and Evolisse at $6.7M. The company delivered positive adjusted EBITDA ($0.6M) for a second consecutive quarter—achieved in seasonally weak Q1—and reiterated full-year 2026 guidance: total net revenue $327M–$337M, adjusted gross margin 65.5%–67%, non-GAAP operating expenses $210M–$216M, and low- to mid-single-digit adjusted EBITDA margin. Key commercial highlights include maintained U.S. toxin share of ~14%, expanding account penetration (over 18,000 purchasing accounts; U.S. penetration >60%), ~71% reorder rates, and ~1.5M Evolus Rewards members (up 27% YoY). Evolisse traction and a portfolio bundling rebate program are driving account expansion and higher repurchase volumes; Sculp approval is expected in Q4 2026 and Esteem launches in Europe mid-May. Management emphasized the Performance Beauty digital ecosystem and AI-driven data platform as durable competitive advantages enabling efficient scaling. Financial position: ~$49.8M cash, access to ~$120M additional capital (term loan and revolving facility), and a terminated ATM facility that was unused. They acknowledged a forthcoming 15% South Korea tariff on certain pharmaceuticals effective 09/29/2026 and are pursuing mitigation strategies, but said this does not change 2026 guidance. Management reaffirmed multi-product growth strategy and long-term outlook through 2028 (double-digit revenue growth and margin expansion).